Literature DB >> 1149368

Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment.

K Verebely, J Volavka, S Mulé, R Resnick.   

Abstract

The biologic disposition of methadone in acute and during chronic administration was studied in 12 human volunteers. In the acute study a biexponential methadone plasma level decay was observed. The acute primary half-life (t1/2) of 14.3 hr in combination with the acute secondary t1/2 of 54.8 hr were longer than the single exponential chronic t1/2 of 22.2 hr determined in the same subjects. The urinary and fecal excretion of methadone and its mono-N-demethylated metabolite increased from 22.2% in the acute to 62.0% in the chronic phase of the study. The urinary metabolite 1 to methadone ratio tripled from the acute to the chronic phase. The pupillary effects of methadone monitored throughout 24 hr were nearly the same in magnitude in the acute and the chronic studies, whereas the plasma levels increased 3- to 8-fold following chronic methadone administration. These findings suggest that both dispositional and pharmacologic tolerance are involved in the development of tolerance following chronic administration of methadone.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1149368     DOI: 10.1002/cpt1975182180

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  36 in total

1.  Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes.

Authors:  A Rostami-Hodjegan; K Wolff; A W Hay; D Raistrick; R Calvert; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

2.  Use of methadone.

Authors:  I B Anderson; T E Kearney
Journal:  West J Med       Date:  2000-01

3.  [Not Available].

Authors:  J Jage
Journal:  Schmerz       Date:  1989-09       Impact factor: 1.107

Review 4.  A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice.

Authors:  R Douglas Bruce; David E Moody; Frederick L Altice; Marc N Gourevitch; Gerald H Friedland
Journal:  Expert Rev Clin Pharmacol       Date:  2013-05       Impact factor: 5.045

Review 5.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

Review 6.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

7.  Methadone and methadone metabolites in postmortem specimens.

Authors:  Terry J Danielson; Ashraf Mozayani; Luis A Sanchez
Journal:  Forensic Sci Med Pathol       Date:  2008-05-30       Impact factor: 2.007

8.  [Presence of methadone in apocrine sweat of the human].

Authors:  S Balabanova; E Schneider; G Bühler; H Krause
Journal:  Z Rechtsmed       Date:  1990

9.  Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts.

Authors:  J W de Vos; P J Geerlings; W van den Brink; J G Ufkes; H van Wilgenburg
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

10.  Pharmacokinetics of methadone during maintenance therapy: pulse labeling with deuterated methadone in the steady state.

Authors:  E Anggård; M I Nilsson; J Holmstrand; L M Gunne
Journal:  Eur J Clin Pharmacol       Date:  1979-08       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.